Fredag 20 November | 16:13:22 Europe / Stockholm
Est. tid*
2026-08-26 - Kvartalsrapport 2026-Q2
2026-05-04 - Årsstämma
2026-03-31 - X-dag ordinarie utdelning FARON 0.00 EUR
2026-03-04 - Bokslutskommuniké 2025
2025-08-27 - Kvartalsrapport 2025-Q2
2025-03-24 - X-dag ordinarie utdelning FARON 0.00 EUR
2025-03-21 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-08-28 - Kvartalsrapport 2024-Q2
2024-03-25 - X-dag ordinarie utdelning FARON 0.00 EUR
2024-03-22 - Årsstämma
2024-03-14 - Bokslutskommuniké 2023
2023-08-29 - Kvartalsrapport 2023-Q2
2023-03-27 - X-dag ordinarie utdelning FARON 0.00 EUR
2023-03-24 - Årsstämma
2023-03-03 - Bokslutskommuniké 2022
2022-08-25 - Kvartalsrapport 2022-Q2
2022-07-07 - Extra Bolagsstämma 2022
2022-04-25 - X-dag ordinarie utdelning FARON 0.00 EUR
2022-04-22 - Årsstämma
2022-03-25 - Bokslutskommuniké 2021
2021-08-26 - Kvartalsrapport 2021-Q2
2021-04-26 - X-dag ordinarie utdelning FARON 0.00 EUR
2021-04-23 - Årsstämma
2021-03-25 - Bokslutskommuniké 2020
2020-05-14 - X-dag ordinarie utdelning FARON 0.00 EUR
2020-05-13 - Årsstämma
2020-03-20 - Bokslutskommuniké 2019
LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriBioteknik
Faron Pharmaceuticals är verksamt inom medicinteknik. Bolaget bedriver forskning och utveckling av terapeutiska lösningar som används för behandling av immuna sjukdomar och diverse organskador. Störst verksamhet återfinns inom Nordamerika samt Europa, med sjukhus och forskningsinstitut som huvudsaklig kundbas. Utöver huvudverksamheten erbjuds diverse mervärdestjänster. Huvudkontoret ligger i Turku.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Faron’s Financial Calendar 2027

2026-11-20 14:00:00

Faron Pharmaceuticals Ltd | Company announcement | November 20, 2026 at 15:00:00 EET

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a global, clinical-stage biopharmaceutical company focused on creating innovative cancer treatments that leverage the patient’s own immune system, today announces the following dates for the Company’s financial reporting in 2027:

3 MarchFinancial statement release for the full year 2026 and Annual Report 2026 including financial statements for the full year
26 AugustHalf-year financial report for the period January 1 to June 30, 2027

The Annual General Meeting is planned to be held on 30 March 2027. A separate stock exchange notice will be issued by Faron’s Board of Directors to convene the meeting.

About bexmarilimab

Bexmarilimab is Faron’s proprietary, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes by targeting myeloid cell function. It binds to Clever-1, a receptor on immunosuppressive macrophages that helps cancer evade the immune system. By targeting Clever-1, bexmarilimab reprograms the tumor microenvironment to ignite a potent anti-tumor immune response.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase 1/2 clinical trials as a potential therapy for patients with hematological cancers and solid tumors in combination with other standard treatments. Further information is available at www.faron.com.

For more information, please contact:

IR Partners, Finland
(Media)
Kare Laukkanen



+358 50 553 9535 / +44 7 469 766 223
kare.laukkanen@irpartners.fi
LifeSci Advisors, US
(Investors) 
Daniel Ferry 

+1 617 430-7576 daniel@lifesciadvisors.com
Cairn Financial Advisers LLP
(Nominated Adviser and Broker)
Sandy Jamieson, Jo Turner

+44 (0) 207 213 0880
Sisu Partners Oy
(Certified Adviser on Nasdaq First North)
Juha Karttunen
Jukka Järvelä

+358 (0)40 555 4727
+358 (0)50 553 8990